gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 31 Oct 2014.

Hepatocyte growth factor

hepatocyte growth factor, HGF, c-Met, scatter factor
Hepatocyte growth factor regulates cell growth, cell motility, and morphogenesis by activating a tyrosine kinase signaling cascade after binding to the proto-oncogenic c-Met receptor. Hepatocyte growth factor is secreted by mesenchymal cells and acts as a multi-functional cytokine on cells of mainly epithelial origin. Its ability to stimulate mitogenesis, cell motility, and matrix invasion gives it a central role in angiogenesis, tumorogenesis, and tissue regeneration. It is secreted as a single inactive polypeptide and is cleaved by serine proteases into a 69-kDa alpha-chain and 34-kDa beta-chain. A disulfide bond between the alpha and beta chains produces the active, heterodimeric molecule. The protein belongs to the plasminogen subfamily of S1 peptidases but has no detectable protease activity. Alternative splicing of this gene produces multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CAN, V1a, HAD, vascular endothelial growth factor, Akt
Papers using hepatocyte growth factor antibodies
Antibodies specifically targeting a locally misfolded region of tumor associated EGFR.
Supplier
Li Jun, In PLoS ONE, 2008
... Total c-MET antibodies included Met (25H2) (Cell Signaling Technology, Danvers, MA) and ...
Phase I trial to determine the dose range for the c-Met inhibitor ARQ197 that inhibits c-Met and FAK phosphorylation, when administered by an oral twice-a-day schedule.
Supplier
Aziz Syed, In PLoS ONE, 2007
... Biosciences, Pleasanton, CA), Human HGF affinity chromatography purified Anti-human HGF (R&D systems, Minneapolis, MN), Anti-human HGF Ab-2 (clone SBF5) (Thermo Scientific, Fremont, CA), human HGF ...
Functional analysis of PIK3CA gene mutations in human colorectal cancer.
Supplier
Shellman Yiqun G., In PLoS ONE, 2004
... 21 and deletion E746-A750 in exon 19) antibodies were from Cell Signaling Technology, anti-HER3 and anti-c-Met antibodies were from Santa Cruz Biotechnology, anti-α-tubulin antibody was from ...
Decorin evokes protracted internalization and degradation of the EGF receptor via caveolar endocytosis
Supplier
Iozzo Renato V. et al., In The Journal of Cell Biology, 2004
... Met C terminus (Santa Cruz Biotechnology, Inc.), Met N terminus (H9786 [Sigma-Aldrich] and AF276 [R&D Systems]), and HGF (Abcam).
more suppliers
Papers on hepatocyte growth factor
Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.
New
Abdel-Rahman, Cairo, Egypt. In Expert Rev Anticancer Ther, 29 Nov 2014
In the past decade, important signaling pathways promoting tumor proliferation and aggressiveness have been evaluated; the hepatocyte growth factor/mesenchymal epithelial transition (MET) pathway is one of the most promising pathways in that regard.
Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
New
Abildgaard et al., Århus, Denmark. In Eur J Haematol, 29 Nov 2014
OBJECTIVES: Syndecan-1 (SDC1), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and interleukin-6 (IL6) are expressed by malignant plasma cells and cells in the bone marrow microenvironment and may be involved in the angiogenic process in multiple myeloma (MM).
Targeted migration of mesenchymal stem cells modified with CXCR4 to acute failing liver improves liver regeneration.
New
Ding et al., Nanjing, China. In World J Gastroenterol, 28 Nov 2014
Either CXCR4-MSCs or Null-MSCs exhibited a paracrine effect through secreting hepatocyte growth factor and vascular endothelial growth factor.
Clinical management of advanced gastric cancer: The role of new molecular drugs.
New
Orditura et al., Napoli, Italy. In World J Gastroenterol, 28 Nov 2014
New molecules targeting vascular epithelial growth factor, mammalian target of rapamycin, and anti hepatocyte growth factor-c-Met pathway are also under investigation, with interesting results.
Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus.
Review
New
Namba et al., Ashiya, Japan. In World J Diabetes, 15 Nov 2014
From another point of view, several reports have supplied augmenting proof that hepatocyte growth factor (HGF) has a physiopathological part in DM involvements.
MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure.
Review
New
Comoglio et al., Torino, Italy. In Curr Opin Cell Biol, 08 Nov 2014
UNLABELLED: The MET oncogene, encoding the hepatocyte growth factor receptor, drives invasive growth, a genetic program largely overlapping with epithelial-mesenchymal transition, and governing physiological and pathological processes such as tissue development and regeneration, as well as cancer dissemination.
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
New
Impact
Loh et al., Baltimore, United States. In Lancet Oncol, Aug 2014
BACKGROUND: Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes tumour growth and metastasis.
mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert).
New
Impact
Rando et al., Stanford, United States. In Nature, Jul 2014
Using genetic mouse models specific to muscle stem cells (or satellite cells), we show that mTORC1 activity is necessary and sufficient for the transition of satellite cells from G0 into G(Alert) and that signalling through the HGF receptor cMet is also necessary.
Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.
Review
New
Impact
Llovet, New York City, United States. In Cancer Cell, Jun 2014
A recent paper describes how VEGF-A stimulates paracrine secretion of hepatocyte growth factor by stromal cells, which induces tumor progression.
CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.
New
Impact
Stassi et al., Palermo, Italy. In Cell Stem Cell, Apr 2014
Cytokines hepatocyte growth factor (HGF), osteopontin (OPN), and stromal-derived factor 1α (SDF-1), secreted from tumor associated cells, increase CD44v6 expression in CR-CSCs by activating the Wnt/β-catenin pathway, which promotes migration and metastasis.
MET and Small-Cell Lung Cancer.
Review
New
Tiseo et al., Milano, Italy. In Cancers (basel), Dec 2013
Among these, the MET/HGF axis seems to be one of the most aberrant signaling pathways involved in SCLC invasiveness and progression.
Mechanisms of hepatocyte growth factor activation in cancer tissues.
Review
New
Kataoka et al., Miyazaki, Japan. In Cancers (basel), Dec 2013
Hepatocyte growth factor/scatter factor (HGF/SF) plays critical roles in cancer progression through its specific receptor, MET.
Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib.
Review
New
Ma et al., Cleveland, United States. In Cancer Manag Res, Dec 2013
MET receptor tyrosine kinase and its natural ligand, hepatocyte growth factor, have been implicated in a variety of cancers, including non-small cell lung cancer (NSCLC).
Obesity-Mediated Regulation of HGF/c-Met Is Associated with Reduced Basal-Like Breast Cancer Latency in Parous Mice.
New
Makowski et al., Chapel Hill, United States. In Plos One, Dec 2013
Our previous work demonstrated that high fat diet-induced obesity in nulliparous mice significantly blunted latency in C3(1)-TAg mice, a model of BBC, potentially through the hepatocyte growth factor (HGF)/c-Met oncogenic pathway.
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
New
Impact
Peterson et al., Chattanooga, United States. In J Clin Oncol, Dec 2013
PURPOSE: Increased hepatocyte growth factor/MET signaling is associated with poor prognosis and acquired resistance to epidermal growth factor receptor (EGFR) -targeted drugs in patients with non-small-cell lung cancer (NSCLC).
Cerebrospinal hepatocyte growth factor levels correlate negatively with disease activity in multiple sclerosis.
GeneRIF
Sadiq et al., New York City, United States. In J Neuroimmunol, 2012
There was decreased expression of hepatocyte growth factor in CSF cells as well as reduced CSF but not plasma HGF levels in multiple sclerosis patients. Patients with active disease had lower hepatocyte growth factor CSF levels than inactive disease.
The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity.
GeneRIF
Hieronymus et al., Aachen, Germany. In J Immunol, 2012
These data unveil Met signaling in dendritic cells as a critical determinant for the maintenance of normal immune function
Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer.
GeneRIF
Tanzawa et al., Saitama, Japan. In Anticancer Res, 2012
levels of HGF and IL-6 in serum could be useful prognostic indicators of the survival of patients with stage III NSCLC undergoing surgery and chemotherapy
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.
Impact
GeneRIF
Bergers et al., San Francisco, United States. In Cancer Cell, 2012
demonstrate that vascular endothelial growth factor (VEGF) directly and negatively regulates tumor cell invasion through enhanced recruitment of the protein tyrosine phosphatase 1B (PTP1B) to a MET/VEGFR2 heterocomplex
Clinical value of serum hepatocyte growth factor, B-cell lymphoma-2 and nitric oxide in primary breast cancer patients.
GeneRIF
Ramadan et al., Cairo, Egypt. In Eur Rev Med Pharmacol Sci, 2012
Serum levels of HGF, Bcl-2 or nitric oxide may help in the diagnosis of breast cancer patients and may aid in disease prognosis.
More papers using hepatocyte growth factor antibodies
Role of receptor tyrosine kinases in lung cancer
Supplier
Salgia Ravi et al., In Journal of Carcinogenesis, 2002
... Total c-Met was obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and ...
SHP-1 negatively regulates neuronal survival by functioning as a TrkA phosphatase
Supplier
Sundan Anders et al., In European Journal of Haematology, 2002
... c-Met from Cell Signaling Technology (Beverly, MA, USA); ...
Phenotypic variation of retinal pigment epithelium in age-related macular degeneration
Supplier
Kim Yeong Hoon et al., In Korean Journal of Ophthalmology : KJO, 2001
... Rabbit anti-human c-Met polyclonal antibody and monoclonal antibody to human c-Met were acquired from Santa Cruz Biotechnology (C-28, Santa Cruz, CA, ...
A method to identify serine kinase substrates. Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain.
Supplier
Sethi Jaswinder K., In PLoS ONE, 2001
... and HEPES were from Invitrogen (Carlsbad, CA), insulin from Lilly (Suresnes, France), PDGF-BB, IGF-1, and HGF from PeproTech (Rocky Hill, NJ), and 2-[3H]deoxyglucose from PerkinElmer Life (Waltham, MA) ...
Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor
Supplier
Bandyopadhyay Sandip K. et al., In Evidence-based Complementary and Alternative Medicine : eCAM, 1999
... EIA kit, nitrate/ nitrite fluorometric assay kit, VEGF and HGF ELISA kits (Cayman Chem., Ann Arbor, MI, ...
Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture
Supplier
Brugge Joan S. et al., In The Journal of Cell Biology, 1998
... Antibodies to CSF-1R and c-Met were obtained from Santa Cruz Biotechnology, Inc.; laminin 5 from Chemicon; ...
Neurofilaments and orthograde transport are reduced in ventral root axons of transgenic mice that express human SOD1 with a G93A mutation
Supplier
Fisher Elizabeth M. C. et al., In Disease Models & Mechanisms, 1996
... Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS ...
Proteoglycans as modulators of growth factor activities
Supplier
Pals Steven T. et al., In The Journal of Experimental Medicine, 1990
... Polyclonal antibodies used were rabbit anti–c-Met, C-12 (IgG) (Santa Cruz Biotechnology ...
share on facebooktweetadd +1mail to friends